People: Senomyx Inc (SNMX.W)
2.01USD
13 May 2013
$0.05 (+2.55%)
$1.96
$2.01
$2.01
$2.01
100
205
$2.81
$1.59
Karanewsky, Donald
Brief Biography
Dr. Donald S. Karanewsky, Ph.D., serves as Senior Vice President, Chief Scientific Officer of Senomyx Inc. From October 2002 to June 2007 Dr. Karanewsky was Executive Director of Chemistry at The Genomics Institute of the Novartis Research Foundation (GNF). At GNF, Dr. Karanewsky had management responsibility for the Departments of Medicinal Chemistry, Analytical Chemistry, Bioanalytical Chemistry, and Compound Management, and was a member of the GNF Drug Discovery Steering Committee and the Novartis Global Discovery Chemistry Leadership Team. Dr. Karanewsky has also directed chemistry research teams and had senior management roles at Ligand Pharmaceuticals and Idun Pharmaceuticals and he previously held principal positions at Glaxo Inc, Bristol-Myers Squibb, and the Squibb Institute for Medical Research. He received his Ph.D. in Chemistry from Harvard University and was granted a B.S. in Chemistry, Magna Cum Laude, from Stevens Institute of Technology in New Jersey. Dr. Karanewsky is an inventor on more than 85 issued US patents and has authored over 70 scientific publications.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 502,969 | -- | 466,253 | 969,222 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Kent Snyder |
2,406,000 |
John Poyhonen |
1,307,860 |
Antony Rogers |
900,531 |
Donald Karanewsky |
969,222 |
David Berger |
936,864 |
Sharon Wicker |
655,955 |

